Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin launches...

    Lupin launches voriconazole tablets

    Written by supriya kashyap kashyap Published On 2016-12-20T11:18:25+05:30  |  Updated On 20 Dec 2016 11:18 AM IST
    Lupin launches voriconazole tablets

    New Delhi : Homegrown pharma major Lupin Ltd announced the launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infections in children.


    Having received approval from the US Food and Drug Administration (USFDA) earlier to market a generic equivalent of PF Prism CV's Vfend tablets, 50 mg and 200 mg and Vfend Oral Suspension 40 mg/mL, the company said it had lanched the same in the US market.


    The medicines are indicated for use in patients 12 years of age and older in the treatment of fungal infections, including invasive Aspergillosis, Candidemia in non-neutropenic patients.


    Besides, it is also used for treatment of Candida infections in skin, and infections in abdomen, kidney, bladder wall and wounds, among others.


    Citing IMS MAT September 2016 data, the company said Vfend Tablets, 50mg & 200mg had US sales of USD 81 million while Vfend Oral Suspension, 40 mg/mL, had US sales of USD 15.2 million.


    Shares of Lupin Ltd were trading at Rs 1,480.50 apiece during mid-day, up 0.81 per cent from the previous close.

    fungal infectionsLupinUS Food & Drug AdministrationUSFDAVfendVfend tabletsVoriconazoleVoriconazole tablets
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok